Takahashi, Shunji
Oridate, Nobuhiko
Tanaka, Kaoru
Shimizu, Yasushi
Fujimoto, Yasushi
Matsumoto, Koji
Yokota, Tomoya
Yamazaki, Tomoko
Takahashi, Masanobu
Ueda, Tsutomu
Hanai, Nobuhiro
Yamaguchi, Hironori
Hara, Hiroki
Yoshizaki, Tomokazu
Yasumatsu, Ryuji
Nakayama, Masahiro
Shiga, Kiyoto
Fujii, Takashi
Mitsugi, Kenji
Takahashi, Kenichi
Nohata, Nijiro
Gumuscu, Burak
Swaby, Ramona F.
Tahara, Makato http://orcid.org/0000-0001-9035-3106
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
https://doi.org/10.1200/jco.21.02508
Checkpoint Inhibitors in Head and Neck Cancer: Current Knowledge and Perspectives
https://doi.org/10.1136/jim-2018-000743
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
https://doi.org/10.1007/s10147-022-02233-6
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
https://doi.org/10.1136/jitc-2020-000664
Funding for this research was provided by:
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Article History
Received: 6 May 2022
Accepted: 3 August 2022
First Online: 20 October 2022
Declarations
:
: Shunji Takahashi has received grants, honoraria, and personal fees from MSD, Eisai, Novartis, Taiho Pharmaceutical Co, Chugai, Bayer, and Daiichi-Sankyo and AstraZeneca. Nobuhiko Oridate has received honoraria from MSD K.K., Tokyo, Japan, Ono Pharmaceutical, Bristol Myers Squibb Japan, Merck Biopharma Japan, and Taiho Pharmaceutical Co. Kaoru Tanaka has received personal fees from AstraZeneca, Merck Biopharma, Eisai, Bristol Myers Squibb, Ono Pharmaceutical, MSD, and Kyowa Kirin. Yasushi Shimizu has received grants and other from MSD. Tomoya Yokota has received grants from AstraZeneca, Chugai Pharma, MSD, Syneos Health, Lilly, Incyte, Novartis, GlaxoSmithKline, and Adlai Nortye; and personal fees from Abbott Japan, Ono Pharmaceutical, Chugai Pharma, Bristol Myers Squibb, Merck Biopharma, MSD, Rakuten Medical, and Eisai. Tomoko Yamazaki has received grants from MSD, AstraZeneca, and GlaxoSmithKline plc. Masanobu Takahashi has received grants from Ono Pharmaceutical; and personal fees from Ono Pharmaceutical, MSD, Bristol Myers Squibb, Daiichi Sankyo, and Taiho Pharmaceutical Co. Tsutomu Ueda has received grants from Ono Pharmaceutical; and personal fees from Ono Pharmaceutical, Merck Biopharma, Mitsubishi Tanabe Pharma, Taiho Pharmaceutical Co, Bayer, and Bristol Myers Squibb. Hiroki Hara has received grants from AstraZeneca, Daiichi Sankyo, Dainippon Sumitomo Pharma, Merck Biopharma, MSD, Taiho Pharmaceutical Co, Chugai, Eisai, Incyte, Boehringer-Ingelheim, Beigene, Ono Pharmaceutical, Astellas, Bayer, Janssen, and Amgen; honoraria from Asahi Kasei, Bayer, Bristol Myers Squibb, Chugai Pharma, Daiichi Sankyo, Kyowa Hakko Kirin, Lilly, Merck Biopharma, MSD, Ono Pharmaceutical, Sanofi, Taiho Pharmaceutical Co, Takeda, and Yakult Honsha; reports leadership roles for Bristol Myers Squibb, Boehringer-Ingelheim, Daiichi Sankyo, Dainippon Sumitomo Pharma, MSD, and Ono Pharmaceutical. Koji Matsumoto has received honoraria from Chugai Pharma and Kyowa Kirin and grants from MSD, Eisai, Chugai Pharma, and Eli Lilly and Company. Yasushi Fujimoto, Nobuhiro Hanai, Hironori Yamaguchi, Tomokazu Yoshizaki, Ryuji Yasumatsu, Masahiro Nakayama, Kenji Mitsugi, and Kiyoto Shiga declare they have no conflicts of interest. Takashi Fuji has received personal fees from Ono Pharmaceutical, Taiho Pharmaceutical Co, Bristol Myers Squibb, Olympus, Merck Biopharma, Eisai, Kyorin Pharmaceutical, and MSD. Kenichi Takahashi is an employee of MSD K.K., Tokyo, Japan and owns stock/stock options in Merck & Co., Inc., Rahway, NJ, USA. Nijiro Nohata is an employee of MSD K.K., Tokyo, Japan and owns stock/stock options in Merck & Co., Inc., Rahway, NJ, USA. Burak Gumuscu is an employee of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and owns stock/stock options in Merck & Co., Inc., Rahway, NJ, USA. Ramona F. Swaby was an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, at the time the study was conducted and owns stock/stock options in Merck & Co., Inc., Rahway, NJ, USA. Makato Tahara has received grants and personal fees from MSD, Ono Pharmaceutical, Bristol Myers Squibb, Bayer, Eisai, Novartis, Pfizer, Rakuten Medical, Merck Biopharma, LOXO, Celgene, and Amgen.